Thus, overall, these data suggest that FEN treatment was beneficial in the treatment of pathologies associated with an obesogenic diet and excess fat gain, thereby attenuating the development of insulin resistance, lipotoxicity and NAFLD/NASH, but at the detriment of the cardiovascular system, at least in genetic mouse models lacking LDLR−/− or ApoE−/−. The gene discussed is LDLR; the disease is metabolic dysfunction-associated steatotic liver disease.